

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10550382	
	Filing Date		2006-08-11	
	First Named Inventor	Martenyi		
	Art Unit	1617		
	Examiner Name	Chong, Yong Soo		
	Attorney Docket Number	PN/4-33153A		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5977099		1999-11-02	NICKOLSON		

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	WO 03/042182	WO		2003-05-22	NOVARTIS AG		<input type="checkbox"/>
	2	EP 0751129	EP		1997-01-02	BENES		<input type="checkbox"/>
	3	WO 97/02250	WO		1997-01-23	PORTELA & CA, S.A.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10550382
Filing Date	2006-08-11
First Named Inventor	Martenyi
Art Unit	1617
Examiner Name	Chong, Yong Soo
Attorney Docket Number	PN/4-33153A

4	WO 03/066039	WO		2003-08-14	ABBOTT LABORATORIES		<input type="checkbox"/>
---	--------------	----	--	------------	------------------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	BENES, "Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10, 11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives." J. Med. Chem., 1999, 42, 2582.	<input type="checkbox"/>
	2	AMBROSIO, "Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024", Neurochem. Res., 2002, 27, 121.	<input type="checkbox"/>
	3	TARTARA, "The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid", Brit. J. Clin. Pharm., 1993, 36, 4, 1, 366.	<input type="checkbox"/>
	4	DIETRICH, "Oxcarbazepine in Affective and Schizoaffective Disorders", Pharmac. Psy., 2001, 34, 6, 242.	<input type="checkbox"/>
	5	WHITE, "Mechanism of action of newer anticonvulsants", J. Clin. Psy., 2003, 64, 8, 39, Abstract.	<input type="checkbox"/>
	6	POPOVA, "Oxcarbazepine in the treatment of bipolar and schizoaffective disorders", Future Drugs, Drug Profile of Oxcarbazepine, 2007, 617.	<input type="checkbox"/>
	7	POPOVA, "Oxcarbazepine in the treatment of bipolar and schizoaffective disorders", Expert Review of Neurotherapeutics, 2007, 7, 6, 617, Abstract.	<input type="checkbox"/>
	8	BOWDEN, "Clinical correlates of therapeutic response in bipolar disorder", J. Affect. Disorder, 2001, 67, 1-3, 257.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10550382
Filing Date	2006-08-11
First Named Inventor	Martenyi
Art Unit	1617
Examiner Name	Chong, Yong Soo
Attorney Docket Number	PN/4-33153A

9	Clinical Trial Data - Licarbazepine 1	<input type="checkbox"/>
10	Clinical Trial Data - Licarbazepine 2	<input type="checkbox"/>
11	Internal Search Report with 35 documents cited	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Yong Chong/	Date Considered	01/11/2010
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.